BREZTRI AEROSPHERE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BREZTRI AEROSPHERE (BREZTRI AEROSPHERE).
Budesonide is a corticosteroid with anti-inflammatory activity; glycopyrrolate is a muscarinic receptor antagonist that inhibits cholinergic bronchoconstriction; formoterol is a long-acting beta2-adrenergic agonist that relaxes bronchial smooth muscle.
| Metabolism | Budesonide: primarily metabolized by CYP3A4; glycopyrrolate: minimal hepatic metabolism; formoterol: primarily metabolized by glucuronidation and O-demethylation via CYP2D6 and CYP2C19. |
| Excretion | Following oral inhalation, budesonide (corticosteroid component) is primarily excreted in urine (60%) and feces (40%) as metabolites. Glycopyrrolate (LAMA) is excreted predominantly unchanged in urine (70%) and feces (30%) after IV administration, with renal excretion as the main route. Formoterol (LABA) is extensively metabolized; approximately 62% of a radiolabeled dose appears in urine and 24% in feces. For the fixed-dose combination, renal elimination of unchanged glycopyrrolate is a major clearance pathway. |
| Half-life | Terminal elimination half-life: budesonide 2.5–3.1 hours, glycopyrrolate 0.5–1.0 hour (inhalation) or 1.3–1.6 hours (IV), formoterol approximately 10 hours after inhalation. Clinical context: Budesonide's short half-life supports once-daily dosing with the co-suspension delivery technology providing prolonged lung retention. Glycopyrrolate's short half-life necessitates twice-daily dosing; formoterol's longer half-life allows twice-daily administration. |
| Protein binding | Budesonide: 85–90% bound to plasma proteins (albumin). Glycopyrrolate: 40–50% bound to plasma proteins. Formoterol: 60–70% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Budesonide: Vd 2.2–3.9 L/kg, indicating extensive tissue distribution. Glycopyrrolate: Vd 0.8–1.2 L/kg (IV) reflecting moderate distribution; with inhalation, lung retention is high. Formoterol: Vd approximately 4 L/kg, suggesting wide distribution. Clinical meaning: Large Vd for budesonide and formoterol implies extensive extravascular binding; for glycopyrrolate, moderate Vd indicates limited peripheral distribution. |
| Bioavailability | Inhalation: Absolute bioavailability of budesonide from the co-suspension formulation is approximately 34% of the delivered dose (low oral bioavailability due to first-pass metabolism). Glycopyrrolate: absolute bioavailability ~13% after inhalation (low oral bioavailability <5%). Formoterol: absolute bioavailability ~15–20% (oral bioavailability ~1% due to extensive first-pass metabolism). Oral bioavailability is negligible for all components. |
| Onset of Action | Inhalation: Bronchodilation (glycopyrrolate/formoterol) within 5 minutes, peak effect at 1–2 hours for FEV1 improvement. Clinically meaningful effects typically observed by Day 1 of treatment. Onset for anti-inflammatory effect (budesonide) is not immediate and requires regular dosing over days to weeks. |
| Duration of Action | Inhalation: Duration of bronchodilation supports twice-daily dosing (12-hour dosing interval). FEV1 improvement sustained over 12 hours after a single dose. Continuous therapy provides 24-hour symptom control with regular twice-daily use. |
| Molecular Weight | Budesonide: 430.5; Glycopyrrolate: 398.3; Formoterol: 344.4 (fumarate: 840.9). Combination product: not applicable. |
| Action Class | Inhaled Corticosteroid/LAMA/LABA Combination |
Two inhalations (each containing budesonide 160 mcg, glycopyrrolate 18 mcg, and formoterol fumarate 4.8 mcg) orally twice daily.
| Dosage form | AEROSOL, METERED |
| Renal impairment | No dosage adjustment required for GFR ≥30 mL/min/1.73 m2. Insufficient data for GFR <30 mL/min/1.73 m2; use with caution. |
| Liver impairment | No dosage adjustment required for Child-Pugh A or B. Not studied in Child-Pugh C; use with caution. |
| Pediatric use | Not indicated for pediatric patients (safety and efficacy not established in children under 18 years). |
| Geriatric use | No specific dose adjustment recommended. Inhaled corticosteroids and long-acting bronchodilators should be used with caution in elderly patients due to potential increased risk of adverse effects (e.g., pneumonia, cardiovascular events). |
| 1st trimester | Insufficient human data; animal studies show no teratogenicity at systemic exposures similar to clinical doses. Use only if benefit outweighs risk. |
| 2nd trimester | Insufficient human data; no known fetal risk from inhaled corticosteroids, LAMAs, or LABAs at recommended doses. Use only if benefit outweighs risk. |
| 3rd trimester | Insufficient human data; potential for fetal growth restriction with high-dose corticosteroids. Use only if benefit outweighs risk. |
Clinical note
Comprehensive clinical and safety monograph for BREZTRI AEROSPHERE (BREZTRI AEROSPHERE).
| Placental transfer | Budesonide: crosses placenta (fetal: maternal ratio ~0.15-0.3 after IV). Glycopyrrolate: no data, but quaternary ammonium compounds have limited placental transfer. Formoterol: limited placental transfer expected based on molecular weight and protein binding. |
| Breastfeeding | Breztri Aerosphere (budesonide/glycopyrrolate/formoterol) is inhaled; systemic absorption is low. Budesonide and formoterol are present in breast milk in low amounts; no data for glycopyrrolate. The American Academy of Pediatrics considers inhaled corticosteroids and long-acting beta-agonists compatible with breastfeeding. Monitor infant for signs of bronchospasm or tachycardia. |
■ FDA Black Box Warning
LABA use increases risk of asthma-related death. BREZTRI AEROSPHERE is not approved for asthma.
| Common Effects | Upper respiratory tract infection, Nasopharyngitis, Headache, Cough, Throat irritation, Dysphonia, Dry mouth, Nausea, Muscle spasms, Dizziness |
| Serious Effects | Pneumonia (in COPD patients), Adrenal insufficiency (with high doses or prolonged use), Paradoxical bronchospasm, Hypersensitivity reactions (anaphylaxis, angioedema), Increased risk of asthma-related death (LABA component), Cardiovascular effects (tachycardia, arrhythmias, hypertension), Hypercorticism (Cushing's syndrome) with high doses, Osteoporosis with long-term use, Glaucoma and cataracts, Urinary retention (anticholinergic effect) |
Hypersensitivity to budesonide, glycopyrrolate, formoterol, or any excipientAcute bronchospasm or status asthmaticus (not for acute episodes)Not indicated for asthma (only for COPD)
| Precautions | LABA-associated increased risk of asthma-related death (not approved for asthma), Deterioration of disease and acute episodes, Cardiovascular effects (excessive beta-adrenergic stimulation: increased heart rate, blood pressure, ECG changes), Paradoxical bronchospasm, Immediate hypersensitivity reactions, Adrenal insufficiency during stress, Reduction in bone mineral density, Use in patients with severe hypersensitivity to milk proteins (contains lactose), Increased risk of pneumonia in COPD patients, Anticholinergic effects (urinary retention, narrow-angle glaucoma) |
Loading safety data…
| Lactation Rating | L3 - Limited data |
| Teratogenic Risk | FDA Pregnancy Category C. No adequate human studies; animal studies show no teratogenicity at clinically relevant doses. Potential risk of reduced fetal growth from high-dose corticosteroids; avoid use in first trimester unless benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal asthma control, fetal growth (ultrasound for growth restriction), and maternal blood pressure. No specific fetal monitoring required beyond standard antenatal care. |
| Fertility Effects | No known effects on fertility in animal studies or human data. Components (budesonide/glycopyrrolate/formoterol) are not associated with impaired fertility. |
| Food/Dietary | No specific food interactions. Grapefruit may increase systemic corticosteroid exposure via CYP3A4 inhibition; advise cautious consumption. No other dietary restrictions. |
| Clinical Pearls | For patients with COPD, BREZTRI AEROSPHERE (budesonide/glycopyrrolate/formoterol fumarate) should be used as maintenance therapy, not for acute exacerbations. Rinse mouth after inhalation to prevent oral candidiasis and dysphonia. Monitor for increased pneumonia risk, especially in patients with asthma. Contraindicated in severe milk protein allergy. Titrate to lowest effective dose. Avoid co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole) due to increased systemic budesonide exposure. |
| Patient Advice | Use this inhaler exactly as prescribed, every day, even if you feel fine. · Do not use for sudden breathing problems; have a rescue inhaler (e.g., albuterol) available. · Rinse your mouth with water after each use, do not swallow the water. · Prime the inhaler before first use and if not used for more than 7 days. · Store at room temperature; do not expose to heat or open flame. · Report any signs of pneumonia (fever, chills, increased sputum) or thrush (white patches in mouth). · Do not change or stop using without consulting your healthcare provider. |